Sign in
TYME Stock Price, Chart, Stats & News
Tyme Technologies, Inc.
Save
Tyme Technologies, Inc. (TYME) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
TYME chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 8.29% |
ROA | -24.62% |
ROE | -23.83% |
D/E | 0.00x |
Interest coverage ratio | -363.21x |
TYME valuation
P/E | – |
P/S | – |
P/B | 0.67x |
P/CF | -2.52x |
P/FCF | – |
P/OCF | -2.52x |
PEG | -0.02x |
EV multiple | -0.63x |
About
Tyme Technologies, Inc. is a biopharmaceutical firm dedicated to developing cancer metabolism-based therapies (CMBTs) within the United States. Its flagship therapeutic candidate, SM-88, is currently undergoing Phase II/III clinical evaluation across 15 distinct cancer types, including but not limited to pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company's pipeline also includes TYME-19, an orally administered synthetic bile acid derivative in preclinical stages for combating SARS-CoV-2 infections, and TYME-18, another preclinical CMBT compound designed to treat tumors that are inoperable.
Similar securities
Based on sector and market capitalization
Report issue